Bevacizumab

Generic Name: Bevacizumab

Brand Names: Avastin, Mvasi, Oyavas, Alymsys, Aybintio, Abevmy, Vegzelma, Onbevzi, Zirabev, Lytenava, Avzivi

Drug Type: Biotech

Chemical Formula: -

CAS Number: 216974-75-3

Unique Ingredient Identifier: 2S9ZZM9Q9V

Background: There is a great deal of evidence indicating that vascular endothelial growth factor (VEGF) is important for the survival and proliferation of cancer cells. VEGF plays an important role in angiogenesis, lymphangiogenesis, and tumor growth, which are all factors that contribute to its attractiveness as a therapeutic target for anti-cancer therapies.
...

Indication: As a vascular endothelial growth factor (VEGF) inhibitor, bevacizumab is used in several chemotherapy regimens to treat metastatic colorectal cancer; metastatic, unresectable, locally advanced or recurrent non-squamous non-small cell lung cancer; metastatic renal cell carcinoma; metastatic, persistent, or recurrent cervical cancer; primary peritoneal cancer;...

Associated Conditions: Metastatic Breast Cancer, Metastatic Cervical Cancer, Metastatic Colorectal Cancer (CRC), Metastatic Non-squamous Non Small Cell Lung Cancer, Metastatic Renal Cell Carcinoma ( mRCC), Persistent Cervical Cancer, Recurrent Cervical Cancer, Recurrent Glioblastoma, Relapsed Glioblastoma, Stage III Fallopian Tube Cancer, Stage III Ovarian Epithelial Cancer, Stage III Primary Peritoneal Cancer, Stage IV Fallopian Tube Cancer, Stage IV Ovarian Epithelial Cancer, Stage IV Primary Peritoneal Cancer, Locally advanced nonsquamous non-small cell lung cancer, Recurrent Non-Squamous Non-Small Cell Lung Cancer, Recurrent Platinum-Sensitive Epithelial Ovarian Cancer, Recurrent Platinum-resistant Epithelial Ovarian Cancer, Recurrent platinum drug resistant Fallopian tube cancer, Recurrent platinum drug resistant primary peritoneal cancer, Recurrent platinum sensitive primary peritoneal cancer, Recurrent platinum-sensitive fallopian tube cancer, Unresectable Non-Squamous Non-Small Cell Lung Cancer, Unresectable, advanced Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC)

Associated Therapies: First Line Chemotherapy, First or Second Line Therapy, Second Line Treatment

Clinical Trials

PD-L1 Antibody + Bevacizumab With Hepatic Arterial Infusion Chemotherapy for Advanced HCC

Phase 2

Recruiting

Conditions: Hepato Cellular Carcinoma (HCC)

Interventions: Drug: PD-L1 antibody
Drug: Bevacizumab
Procedure: HAIC-FOLFOX

First Posted Date: 2024-12-19

Last Posted Date: 2024-12-19

Lead Sponsor: West China Hospital

Target Recruit Count: 36

Registration Number: NCT06742424

Locations: 🇨🇳
West China Hospital, Chengdu, Sichuan, China

Fluzoparib With or Without Bevacizumab for Neoadjuvant Therapy in Advanced Ovarian Cancer

Phase 2

Recruiting

Conditions: Ovarian Cancer
Fallopian Tube Cancer
Peritoneal Cancer

Interventions: Drug: Fluzoparib
Drug: Paclitaxel
Drug: Bevacizumab
Drug: Carboplatin

First Posted Date: 2024-12-16

Last Posted Date: 2024-12-16

Lead Sponsor: Qilu Hospital of Shandong University

Target Recruit Count: 105

Registration Number: NCT06735326

Locations: 🇨🇳
Qilu Hospital of Shandong University, Jinan, Shandong, China

FOLFOXIRI Plus Bevacizumab With or Without Atezolizumab as 1st Line Treatment of pMMR and IS IC-High Metastatic Colorectal Cancer Patients.

Phase 3

Recruiting

Conditions: Colorectal Cancer

Interventions: Drug: Bevacizumab
Drug: Atezolizumab
Drug: Irinotecan (CPT-11)
Drug: Oxaliplatin
Drug: Leucovorin
Drug: Fluorouracil (5-FU)

First Posted Date: 2024-12-13

Last Posted Date: 2024-12-16

Lead Sponsor: Gruppo Oncologico del Nord-Ovest

Target Recruit Count: 238

Registration Number: NCT06733038

Locations: 🇮🇹
Istituto Oncologico Veneto Irccs, Padova, PD, Italy
🇮🇹
Nuovo Ospedale di Prato S. Stefano, Prato, PO, Italy
🇮🇹
U.O. Oncologia Medica 2 Universitaria - Azienda Ospedaliero-Universitaria Pisana Dipartimento di Ricerca Traslazionale e Nuove Tecnologie - University of Pisa, Pisa, Italy

A Study of BMS-986490 With or Without Bevacizumab in Advanced Solid Tumors

Phase 1

Not yet recruiting

Conditions: Advanced Solid Tumors

Interventions: Drug: BMS-986490
Drug: Bevacizumab

First Posted Date: 2024-12-12

Last Posted Date: 2024-12-12

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 360

Registration Number: NCT06730750

Locations: 🇺🇸
Local Institution - 0007, Los Angeles, California, United States
🇺🇸
Local Institution - 0017, Grand Rapids, Michigan, United States
🇺🇸
Local Institution - 0004, Hackensack, New Jersey, United States

and more 3 locations

Study of SHR-A1811 Combined with Pyrotinib and Bevacizumab in Advanced Breast Cancer with Brain Metastasis

Phase 1

Not yet recruiting

Conditions: Breast Cancer Metastatic
Breast Cancer Brain Metastases

Interventions: Drug: SHR-A1811
Drug: Pyrotinib
Drug: Bevacizumab

First Posted Date: 2024-12-05

Last Posted Date: 2024-12-05

Lead Sponsor: Fudan University

Target Recruit Count: 74

Registration Number: NCT06718933

Locations: 🇨🇳
Fudan Cancer Hospital, Shanghai, Shanghai, China

Clinical Trial of an Anti-cancer Drug, CA-4948 (Emavusertib), in Combination With Chemotherapy Treatment (FOLFOX Plus Bevacizumab) in Metastatic Colorectal Cancer

Phase 1

Not yet recruiting

Conditions: Metastatic Colorectal Adenocarcinoma
Stage III Colorectal Cancer AJCC v8
Stage IV Colorectal Cancer AJCC v8
Unresectable Colorectal Adenocarcinoma

Interventions: Biological: Bevacizumab
Procedure: Biopsy
Procedure: Biospecimen Collection
Procedure: Computed Tomography
Biological: Emavusertib
Drug: Fluorouracil
Drug: Leucovorin Calcium
Procedure: Magnetic Resonance Imaging
Drug: Oxaliplatin
Procedure: Positron Emission Tomography

First Posted Date: 2024-11-20

Last Posted Date: 2024-12-11

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 24

Registration Number: NCT06696768

A Study of BMS-986482 Alone or as Combination Therapy in Participants With Advanced Solid Tumors

Phase 1

Not yet recruiting

Conditions: Advanced Solid Tumors

Interventions: Drug: BMS-986482
Drug: Nivolumab and rHuPH20
Drug: Nivolumab/relatlimab/rHuPH20
Drug: Bevacizumab

First Posted Date: 2024-11-20

Last Posted Date: 2024-12-18

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 413

Registration Number: NCT06697197

Locations: 🇺🇸
Local Institution - 0030, Los Angeles, California, United States
🇺🇸
Local Institution - 0005, Irvine, California, United States
🇺🇸
Local Institution - 0008, Aurora, Colorado, United States

and more 4 locations